Disruption of the mdm2-p53 interaction by introducing molecules that inhibit mdm2, restore wtp53 and stabilize the active conformation of the p53 protein [14, 18] may offer an effective therapeutic approach, attracting more attention for HCC over recent years [19–21]. Here, TP53 is linked to hepatocellular carcinoma.